Analysis of patent litigation, PTAB practice, prosecution and pharma IP, written on the data behind LexDana.
Tagged life sciences · clear
Written by : Agnes Juang, Ph.D. and Ashley C. Morales Key Takeaway: Genetically engineered cultured host cells containing recombinant nucleic acids useful for gene therapy are patent-eligible for being markedly different from anything occurring in nature.…
Written by : Ari Feinstein and Sophia Zahn On December 5, 2025, the Skinny Labels, Big Savings Act (H.R. 6485) was introduced in the House of Representatives. The bill, if enacted, would shield certain drug manufacturers who have submitted drug…
Written by : Ari Feinstein and Sophia Zahn On December 5, 2025, the Skinny Labels, Big Savings Act (H.R. 6485) was introduced in the House of Representatives. The bill, if enacted, would shield certain drug manufacturers who have submitted drug…
Written by : Robert J. Hilton, Ph.D. and Susan M. Janicki, Ph.D. On November 26, 2025, the United States Patent and Trademark Office (USPTO) issued revised guidelines for determining inventorship of AI-assisted inventions, [1] which is a significant…
Written by : Jason J. Jardine and Geetha Durairaj, Ph.D. In October 2025, the U.S. Patent and Trademark Office (USPTO) launched the “ Artificial Intelligence Search Automated Pilot Program ,” or ASAP!, an initiative to identify potential prior…
Written by : Jane Dai, Ph.D . and Geetha Durairaj, Ph.D. On May 12, 2025, the U.S. Court of Appeals for the Federal Circuit (CAFC) revived the Regents of the University of California's (Regents) challenge to the Broad Institute's CRISPR-Cas9…
Written by : Alistair J. McIntyre and Agnes Juang, Ph.D. On March 17, 2025, a bipartisan group of senators introduced two bills intended to decrease the cost of prescription drugs. The sponsors include Chuck Grassley (R-Iowa), John Cornyn (R-Texas),…
Written by : Bailey R. Arenberg and Jason J. Jardine Effective January 28, 2025, the new administration suspended the Climate Change Mitigation Pilot Program (CCMPP) at the United States Patent and Trademark Office (USPTO). [1] The USPTO had instituted…
Written by : Bailey R. Arenberg & Jason J. Jardine With the recent convocation of the 119 th Congress, a change in administration, and resignation of USPTO Director Vidal, pharmaceutical patent reform is likely on the minds of many in Washington. Prior to…
Written by : Ari Feinstein and Joseph Mallon, Ph.D. On October 11, 2024, Edwards [1] filed a petition for a writ of certiorari with the U.S. Supreme Court. [2] The question presented, as framed by Edwards, is: “Whether, under Hatch-Waxman’s…
Written by : Jason J. Jardine , Justin Culbertson, Ph.D. & Phillip J. Minnick, Ph.D. The sun is officially setting on the United States Patent and Trademark Office’s (USPTO) After Final Consideration Pilot Program 2.0 (AFCP 2.0) [1] . This program,…
Written by : Kenneth O. Aruda, Ph.D. & J ason J. Jardine In the ongoing case of Carefirst of Maryland Inc. v. Johnson & Johnson [1] , the plaintiffs successfully overcame a motion to dismiss. At the heart of the case is J&J’s legal strategy against…
